Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin A  COVID-19 treatment studies for Vitamin A  C19 studies: Vitamin A  Vitamin A   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Hospitalization 21% Improvement Relative Risk Severe case 21% c19early.com/va Nimer et al. Vitamin A for COVID-19 Prophylaxis Favors vitamin A Favors control
Nimer, 2,148 patient vitamin A prophylaxis study: 21% lower hospitalization [p=0.4] and 21% lower severe cases [p=0.36] https://c19p.org/nimera
copied to clipboard
The impact of vitamin and mineral supplements usage prior to COVID-19 infection on disease severity and hospitalization
Nimer et al., Bosnian Journal of Basic Medical Sciences, doi:10.17305/bjbms.2021.7009
28 Feb 2022    Source   PDF   Share   Tweet
Retrospective survey based analysis of 2,148 COVID-19 recovered patients in Jordan, showing no significant differences in the risk of severity and hospitalization with vitamin A prophylaxis.
risk of hospitalization, 21.2% lower, RR 0.79, p = 0.40, treatment 15 of 144 (10.4%), control 204 of 2,004 (10.2%), adjusted per study, odds ratio converted to relative risk, multivariable.
risk of severe case, 20.8% lower, RR 0.79, p = 0.36, treatment 17 of 144 (11.8%), control 243 of 2,004 (12.1%), adjusted per study, odds ratio converted to relative risk, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Nimer et al., 28 Feb 2022, retrospective, Jordan, peer-reviewed, survey, 4 authors, study period March 2021 - July 2021.
Contact: rmnimer@just.edu.jo.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin AAll
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit